NIH-sponsored study supports cabotegravir use throughout period of reproductive potential

Tuesday, July 23, 2024 Long-acting injectable cabotegravir for HIV prevention is safe in pregnancy Transmission electron micrograph of HIV-1 virus particles (green) replicating from the plasma membrane of an H9 T cell (pink). Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID. A NIAID-sponsored study found long-acting injectable cabotegravir was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) prior to and during pregnancy. Results from the global study and outcomes from more than 300 pregnancies and infants will be presented on July 25 at the 2024 International AIDS Conference (AIDS 2024) in Munich, Germany. Learn More National Institute of Allergy and Infectious Diseases  |  National Institutes of Health

---

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period. 

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).

                           

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107